As investments in life science companies have dipped over the past few years, some investors have scaled back investments or walked away from the sector all together. But based on a tally by investment research firm PitchBook in its 2013 Venture Capital Healthcare Report, several firms have made 10 or more investments in pharmaceutical, medical […]
While many healthcare venture capital firms continue to ease away from early-stage deals, Third Rock Ventures has just restocked with $516 million to continue backing them. With its third fund, the Boston and San Francisco-based venture firm says it will launch, build and support up to 16 healthcare companies. Its investment strategy hinges on backing […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
There’s no shortage of innovative approaches to helping people lose weight today, whether it’s filling space in the stomach to create an artificial sense of fullness, using neuromodulation to keep hunger at bay, or using online or mobile tracking tools. But this company is taking a different approach, aiming at the biological underpinnings of obesity […]
Venture capital firm Third Rock Ventures has launched a drug development startup to treat genetic blood disorders, with sickle-cell anemia as its lead program target, providing $40.7 million in series A financing. Global Blood Therapeutics‘ drug development pipeline will target severe, genetic blood diseases that currently have no effective cures and limited therapeutic options. It […]
How much more likely would a diabetic be to check his blood sugar regularly, or a nervous patient to fulfill her doctor’s request for blood work, if there were no “ouch” factor involved? Howard Weisman, the CEO of Seventh Sense Biosystems, said the painless blood draw system his company is developing could show us the […]
Swiss drugmaker Novartis just got Food and Drug Administration approval to sell the first pill that can slow the progression of multiple sclerosis. Gilenya will go head-to-head with injectable medicines, including Avonex, Tysabri and Rebif. But how much will the MS pill cost? Novartis won't say, NPR reports.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Boston investment firm Third Rock Ventures LLC has raised $426 million for its second (oversubscribed) fund and is opening a San Francisco office to continue its practice of "launching and supporting transformative life sciences companies." Who says the venture capital industry is in the doldrums?